The Francis Crick Institute
Browse
1-s2.0-S240580332400089X-main (1).pdf (2.11 MB)

Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer.

Download (2.11 MB)
journal contribution
posted on 2024-07-10, 11:07 authored by Chris Abbosh, Darren Hodgson, Gary J Doherty, Davina Gale, James RM Black, Leora Horn, Jorge S Reis-Filho, Charles Swanton
Systemic treatment of resectable non-small cell lung cancer (NSCLC) is evolving with emerging neoadjuvant, perioperative, and adjuvant immunotherapy approaches. Circulating tumor DNA (ctDNA) detection at clinical diagnosis, during neoadjuvant therapy, or after resection may discern high-risk patients who might benefit from therapy escalation or switch. This Review summarizes translational implications of data supporting ctDNA-based risk determination in NSCLC and outstanding questions regarding ctDNA validity/utility as a prognostic biomarker. We discuss emerging ctDNA capabilities to refine clinical tumor-node-metastasis (TNM) staging in lung adenocarcinoma, ctDNA dynamics during neoadjuvant therapy for identifying patients deriving suboptimal benefit, and postoperative molecular residual disease (MRD) detection to escalate systemic therapy. Considering differential relapse characteristics in landmark MRD-negative/MRD-positive patients, we propose how ctDNA might integrate with pathological response data for optimal postoperative risk stratification.

Funding

Crick (Grant ID: CC2041, Grant title: Swanton CC2041)

History